401～500

401. Lin A, Mahle WT, Frias PA, et al. Early and delayed atrioventricular conduction block after routine surgery for congenital heart disease. J Thorac

Cardiovasc Surg 2010; 140: 158-160.

402. Batra AS, Balaji S. Pacing in adults with congenital heart disease. Expert Rev Cardiovasc Ther 2006; 4: 663-670.

403. Khairy P, Landzberg MJ, Gatzoulis MA, et al. Transvenous pacing leads and systemic thromboemboli in patients with intracardiac shunts:

a multicenter study. Epicardial Versus ENdocardial pacing and Thromboembolic event s Investigators. Circulation 2006; 113: 2391-2397.

404. Oechslin EN, Harrison DA, Connelly MS, et al. Mode of death in adults with congenital heart disease. Am J Cardiol. 2000; 86: 1111-1116.

405. Alexander ME, Cecchin F, Walsh EP, et al. Implications of implantable cardioverter defibrillator therapy in congenital heart disease and pediatrics. J

Cardiovasc Electrophysiol 2004; 15: 72-76.

406. Stephenson EA, Batra AS, Knilans TK, et al. A multicenter experience with novel implantable cardioverter defibrillator configurations in the pediatric

and congenital heart disease population. J Cardiovasc Electrophysiol 2006; 17: 41-46.

407. Yap SC, Roos-Hesselink JW, Hoendermis ES, et al. Outcome of implantable cardioverter defibrillators in adults with congenital heart disease: a multi-

centre study. Eur Heart J 2007; 28: 1854-1861.

408. Berul CI, Van Hare GF, Kertesz NJ, et al. Results of a multicenter retrospective implantable cardioverterdefibrillator registry of pediatric and congenital

heart disease patients. J Am Coll Cardiol 2008; 51: 1685-1691.

409. Witte KK, Pepper CB, Cowan JC, et al. Implantable cardioverter-defibrillator therapy in adult patients with tetralogy of Fallot. Europace 2008; 10: 926-

930.

410. Radbill AE, Triedman JK, Berul CI, et al. System survival of nontransvenous implantable cardioverter-defibrillators compared to transvenous

implantable cardioverterdefibrillators in pediatric and congenital heart disease patients. Heart Rhythm 2010; 7: 193-198.

411. Silversides CK, Kiess M, Beauchesne L, et al. Canadian Cardiovascular Society 2009 Consensus Conference on the management of adults with

congenital heart disease: outflow tract obstruction, coarctation of the aorta, tetralogy of Fallot, Ebstein anomaly and Marfan’s syndrome.

Can J Cardiol 2010; 26: e80-97.

412. Dimopoulos K, Inuzuka R, Goletto S, et al. Improved survival among patients with Eisenmenger syndrome receiving advanced therapy for pulmonary

arterial hypertension. Circulation 2010; 121: 20-25.

413. Galie N, Beghetti M, Gatzoulis MA, et al. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-

controlled study. Circulation 2006; 114: 48-54.

414. Gatzoulis MA, Beghetti M, Galie N, et al. Longer-term bosentan therapy improves funct ional capaci ty in Eisenmenger syndrome: results of the

BREATHE-5 openlabel extension study. Int J Cardiol 2008; 127: 27-32.

415. D’Alto M, Vizza CD, Romeo E, et al. Long term effects of bosentan treatment in adult patients with pulmonary arterial hypertension related to

congenital heart disease (Eisenmenger physiology): safety, tolerability, clinical, and haemodynamic effect. Heart 2007; 93: 621-625.

416. Mehta PK, Simpson L, Lee EK, et al. Endothelin receptor antagonists improve exercise tolerance and oxygen saturations in patients with

Eisenmenger syndrome and congenital heart defects. Tex Heart Inst J 2008; 35: 256-261.

417. Durongpisitkul K, Jakrapanichakul D, Sompradikul S. A retrospective study of bosentan in pulmonary arterial hypertension associated with congenital

heart disease. J Med Assoc Thai 2008; 91: 196-202.

418. Diller GP, Dimopoulos K, Kaya MG, et al. Long-term safety, tolerability and efficacy of bosentan in adults with pulmonary arterial hypertension

associated with congenital heart disease. Heart 2007; 93: 974-976.

419. Apostolopoulou SC, Manginas A, Cokkinos DV, et al. Long-term oral bosentan treatment in patients with pulmonary arterial hypertension related to

congenital heart disease: a 2-year study. Heart 2007; 93: 350-354.

420. Sitbon O, Beghetti M, Petit J, et al. Bosentan for the treatment of pulmonary arterial hypertension associated with congenital heart defects. Eur J Clin

Invest 2006; 36 Suppl 3: 25-31.

421. Benza RL, Rayburn BK, Tallaj JA, et al. Efficacy of bosentan in a small cohort of adult patients with pulmonary arterial hypertension related to

congenital heart disease. Chest 2006; 129: 1009-1015.

422. Singh TP, Rohit M, Grover A, et al. A randomized, placebocontrolled, double-blind, crossover study to evaluate the efficacy of oral sildenafil therapy in

severe pulmonary artery hypertension. Am Heart J 2006; 151: 851 e1-5.

423. Mukhopadhyay S, Sharma M, Ramakrishnan S, et al. Phosphodiesterase-5 inhibitor in Eisenmenger syndrome: a preliminary observational study.

Circulation 2006; 114: 1807-1810.

424. Archer S, Michelakis ED. Phosphodiesterase type 5 inhibitors for pulmonary arterial hypertension. N Engl J Med 2009; 361: 1864-1871.

425. Fernandes SM, Newburger JW, Lang P, et al. Usefulness of epoprostenol therapy in the severely ill adolescent/adult with Eisenmenger physiology.

Am J Cardiol 2003; 91: 632-635.

426. Kuhn KP, Byrne DW, Arbogast PW, et al. Outcome in 91 consecutive patients with pulmonary arterial hypertension receiving epoprostenol.

Am J Respir Crit Care Med 2003; 167: 580-586.

427. Vachiery J, Hill N, Zwicke D, et al. Transitioning from iv epoprostenol to subcutaneous treprostinil in pulmonary arterial hypertension. Chest 2002; 121:

1561-1565.

428. Galie N, Manes A, Palazzini M, et al. Management of pulmonary arterial hypertension associated with congenital systemic-to-pulmonary shunts and

Eisenmenger’s syndrome. Drugs 2008; 68: 1049-1066.

429. Barst RJ, Gibbs SR, Ghofrani HA, et al. Updated evidencebased treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol 2009; 54:

S78-84.

430. Fox JM, Biornsen KD, Mahoney LT, et al. Congenital heart disease in adults: catheterization laboratory considerations. Catheter Cardiovasc Interv

2003; 58: 219-231.

431. British Cardiac Society. Report of the British Cardiac Society Working Party. Grown-up congenital heart disease: current needs and provision of

service for adolescent and adults with congenital heart disease in the UK. Heart 2002; 88 (Suppl I): i1-14.

432. Gurvitz MZ, Chang RK, Ramos FJ, et al. Variations in adult congenital heart disease training in adult and pediatric cardiology fellowship programs. J

Am Coll Cardiol 2005; 46: 893-898.

433. Warnes CA, Liberthosn R, Danielson GH, et al. Task Force 1: The changing profile of congenital heart disease in adult life. J Am Coll Cardiol 2001; 37:

1170-1175.

434. Srinathan SK, Bonser RS, Sethia B, et al. Changing practice of cardiac surgery in adult patients with congenital heart disease. Heart 2004; 91: 207-

212.

435. Carminati M, Chessa M, Butera G, et al. Transcatheter closure of atrial septal defects with the STARFlex device: early results and follow-up. J Interv

Cardiol 2001;14: 319-324.

436. Thanopoulos BD, Laskari CV, Tsaousis GS, et al. Closure of atrial septal defects with the Amplatzer Occlusion Device: Preliminary results. J Am Coll

Cardiol 1998; 31: 1110-1116.

437. Oho S, Ishizawa A, Akagi T, et al. Transcatheter closure of atrial septal defects with Amplatzer septal occluder. A Japanese clinical trial. Circulation J

2002; 66:9: 791-794.

438. Du ZD, Hijazi ZM, Kleinman CS, et al. Amplatzer Investigators. Comparison between transcatheter and surgical closure of secundum atrial septal

defect in children and adults: results of a multicenter nonrandomized trial. J Am Coll Cardiol 2002; 39: 1836-1844.

439. Chessa M, Butera G, Carminati M. Risk of thrombus formation on devices used to close transcatheter atrial septal defect and patent foramen ovale. J

Am Coll Cardiol 2004; 44: 1712.

440. Gatzoulis MA, Redington AN, Somerville J, et al. Should atrial septal defects in adults be closed? Ann Thorac Surg 1996; 61: 657-659.

441. Ewert P, Berger F, Nagdyman N, et al. Masked left ventricular restriction in elderly patients with atrial septal defects: a contraindication for closure?

Catheter Cardiovasc Interv 2001; 52: 177-180.

442. Divekar A, Gaamangwe T, Shaikh N, et al. Cardiac perforation after device closure of atrial septal defects with the　Amplatzer septal occluder. J Am

Coll Cardiol 2005; 45: 1213-1218.

443. Khan AA, Tan JL, Li W, et al. The impact of transcatheter atrial septal defect closure in the older population. JACC Cardiovasc Interv 2010; 3: 276-281.

444. Jategaonkar S, Scholtz W, Schmidt H, et al. Percutaneous closure of atrial septal defects: Echocardiographic and functional results in patients older

than 60 Years. Circ Cardiovasc Intervent 2009; 2: 85-89.

445. Taniguchi M, Akagi T, Ohtsuki S, et al. Transcatheter closure of atrial septal defect in elderly patients with permanent atrial fibrillation. Catheter

Cardiovasc Interv 2009; 73: 682-686.

446. Cambier PA, Kirby WC, Wortham DC, et al. Percutaneous closure of the small (< 2.5mm) patent ductus arteriosus using coil embolization.

Am J Cardiol 1992; 69: 815-816.

447. Akagi T, Hashino K, Sugimura T, et al. Coil occlusion of patent ductus arteriosus using detachable coils. Am Heart J 1997; 134: 583-543.

448. Akagi T, Mizumoto Y, Iemura M, et al. Catheter closure of moderate to large sized patent ductus arteriosus using the simultaneous double or triple

coil

technique. Pediatrics International 2001: 43; 536-541.

449. Masura J, Walsh KP, Thanopoulous B, et.al. Catheter closure of moderate- to large-sized patent ductus arteriosus using the new Amplatzer Duct

Occluder: Immediate and short-term results. J Am Coll Cardiol 1998; 31: 878-882.

450. Patel HT, Cao QL, Rhodes J, et al. Long term outcome of transcatheter coil closure of small to large patent ductus arteriosus. Catheter Cardiovasc

Interv 1999; 47: 457-461.

451. Pass RH, Hijazi Z, Hsu DT, et al. Multicenter USA Amplatzer patent ductus arteriosus occlusion device trial: initial and one-year results. J Am Coll

Cardiol 2004; 44: 513-519.

452. Dimas VV, Takao C, Ing FF, et al . Outcomes of transcatheter occlusion of patent ductus arteriosus in infants weighing <6 kg. JACC Cardiovasc Interv

2010; 3: 1295-1299.

453. ACC/AHA guidelines for the management of patients with Valvular heart disease. A report of the American College of Cardiology/American Heart

Association. Task force on Practice Guidelines. J Am Coll Cardiol 1998; 32: 1486-1588.

454. Backer CM, McGowan FX Jr, Keane JF, et al. Pulmonary artery trauma due to balloon dilatation: recognition, avoidance and management. J Am Coll

Cardiol 2000; 36: 1684-1690.

455. Trivedi KR, Benson LN. Interventional strategies in the management of peripheral pulmonary artery stenosis. J Interv Cardiol 2003; 16: 171-188.

456. Ovaert C, Benson LN, Nykanem D, et al. Transcatheter treatment of coarctation of the aorta: a review. Pediatr Cardiol 1998; 19: 27-44.

457. Hamdam MA, Maheshwari S, Fahey JT, et al. Endovascular stents for coarctation of the aorta: initial results and intermediate-term follow-up. J Am

Coll

Cardiol 2001; 38: 1518-1523.

458. Forbes T, Matisoff D, Dysart J, et al. Treatment of coexisting coarctation and aneurysm of the aorta with covered stent in a pediatric patient. Pediatr

Cardiol 2003; 24: 289-291.

459. Perry SB, Rome J, Keane JF, et al. Transcatheter closure of coronary artery fistulas. J Am Coll Cardiol 1992; 20: 205-209.

460. Ogoh Y, Akagi T, Abe T, et al. Successful embolization of coronary arteriovenous fistula using an interlocking detachable coil. Pediatric Cardiology

1997; 18: 152-155.

461. Thanopoulos BD, Tsaousis GS, Konstadopoulou GN, et al. Transcatheter closure of muscular ventricular septal defects with the Amplatzer ventricular

septal defect occluder: Initial clinical applications in children. J Am Coll Cardiol 1999; 33: 1395-1399.

462. Hijazi M, Hakim F, Haweleh A, et al. Catheter closure of perimembranous ventricular septal defects using the Amplatzer Membranous VSD Occluder.

Cathet Cardiovasc Intervent 2002; 56: 508-515.

463. Mullasari AS, Umesan CV, Krishnan U, at al. Transcatheter closure of post-myocardial infarction ventricular septal defect with Amplatzer septal

occluder. Cathet Cardiovasc Intervent 2001; 54: 484-487.

464. Martin F, Sanchez PL, Doherty E, et al. Percutaneous transcatheter closure of patent foramen ovale in patients with paradoxical embolism. Circulation

2002; 106; 1211-1126.

465. Ford MA, Reeder GS, Lennon RJ, et al. Percutaneous device closure of patent foramen ovale in patients with presumed cryptogenic stroke or transient

ischemic attack: the Mayo Clinic experience. JACC Cardiovasc Interv 2009; 2: 404-411.

466. Zimmermann WJ, Heinisch C, Majunke N, et al. Patent foramen ovale closure with the SeptRx device initial experience with the first “In-Tunnel”

device. JACC Cardiovasc Interv 2010; 3: 963-967.

467. Van den Branden BJ, Post MC, Plokker HW, et al. Patent foramen ovale closure using a bioabsorbable closure device: safety and efficacy at 6-month

follow-up. JACC Cardiovasc Interv 2010; 3: 968-973.

468. Bonhoeffer P, Boudjemline Y, Saliba Z, et al. Transcatheter implantation of a bovine valve in pulmonary position: A lamb study. Circulation 2000; 102:

813-816.

469. Boudjemline Y, Agnoletti G, Bonnet D, et al. Percutaneous pulmonary valve replacement in a large right ventricular outflow tract: an experimental

study. J Am Coll Cardiol 2004; 43: 1082-1087.

470. Vezmar M, Chaturvedi R, Lee KJ, et al. Percutaneous pulmonary valve implantation in the young 2-year follow-up. JACC Cardiovasc Interv 2010; 3:

439-448.

471. Tan J, de Swiet M. cardiac disease in pregnancy. PACE review no 98/02. London: Royal College of Obstetricians and Gynaecologists.

472. MaCaffrey FM, Sherman FS. Pregnancy and congenital heart disease: The Magee Women’s Hospital. J Matern Fetal Med 1995; 4: 152-159.

473. Kamiya C, Nakatani S, Hashimoto S, et al. Role of echocardiography in assessing pregnant women with and without heart disease. J

Echocardiography 2008; 6: 29-38.

474. DeWilde JP, Rivers AW, Price DL. A review of the current use of magnetic resonance imaging in pregnancy and safety implications for fetus. Prog

Biophys Mol Biol 2005; 87: 335-353.

475. Freeman RK, Garite TJ, Nageotte MP. Fetal Heart Rate Monitoring (2nd ed). Williams & Wilkins 1991: 158-177.

476. 松田義雄. 胎児well-beingの評価法とその問題点. 日小循誌 2001; 17: 518-525.

477. Cunningham FG, MacDonald PC, Gant NF, et al. Williams Obstetrics (20th ed) Appleton & Lange 1997: 1012-1013.

478. Manning FA. Fetal biophysical profile scoring. Fetal Medicine: Principles and Practice. (Manning FA, eds). Appleton & Lange 1995: 262.

479. Devoe LD. Antepartum Fetal Surveillance. Current Therapy in Obstetrics and Gynecology (5th ed) (Quilligan EJ, Zuspan FP, eds). W.B.Saunders

Company 2000: 372-375.

480. Wladimiroff JW. Cerebral and umbilical artery blood flow velocity waveforms in normal and growth retarded pregnancies. Obstet Gynecol 1987; 69:

705-709.

481. Cunningham FG, Leveno KJ, Bloom SL, et al. Williams Obstetrics (23th ed) McGraw Hill 2005: 804-831.

482. Robson SC, Dunlop W, Boys RJ, et al. Cardiac output during labour. Br Med J 1987; 295: 1169-1172.

483. Siu SC, Jack M, Colman JM. Heart disease and pregnancy Heart 2001; 85: 710-715.

484. Siu SC, Colman JM, Sorensen S, et al. Adverse neonatal and cardiac outcomes are more common in pregnant women with cardiac disease.

Circulation 2002; 105: 2179-2184.

485. Siu SC, Sermer M, Colman JM, et al. Prospective multicenter study of pregnancy outcomes in women with heart disease. Circulation 2001;104: 515-

521.

486. Khairy P, Ouyang DW, et al. Pregnancy outcomes in women with congenital heart disease. Circulation 2006; 113: 517-524.

487. American College of Obstetricians and Gynecologists: Cardiac diseases in pregnancy. Technical Bulletin No 168, June 1992a.

488. Blanchard DG. Cardiac diseases Maternal-Fetal Medicine 5th edition, saunders, Philadeiphia 2004: 815-843.

489. Gleicher N. Eisenmenger syndrome and pregnancy. Obstet Gynecol Surv 1979; 34: 721-741.

490. Yentis SM, Steer PJ, Plaat F. Eisenmenger’s syndrome in pregnancy: maternal and fetal motality in the 1990s. British J Obstet Gynecol 1998; 105:

921-922.

491. Weiss BM, Zemp L, Seifert B, et al. Outcome of pulmonary vascular disease in pregnancy: A systematic overview from 1978 through 1996. J Am Coll

Cardiol 1998; 31: 1650-1657.

492. Geohas C, McLaughlin VV. Successful management of pregnancy in a patient with eisenmenger syndrome with epoprostenol. Chest 2003; 124: 1170-

1173.

493. Lacassie HJ, Germain AM, Valdés G, et al. Management of Eisenmenger syndrome in pregnancy with sildenafil and L-arginine. Obstet Gynecol 2004;

103: 1118-1120.

494. Shime J, Mocarski EJ, Hastings D, et al. Congenital heart disease in pregnancy: short-and long-term implications. Am J Obstet Gynecol 1987; 156:

313-322.

495. Presbitero P, Somerville J, Stone S, et al. Pregnancy in cyanotic congenital heart disease; outcome of mother and fetus. Circulation 1994; 89: 2673-

2676.

496. Rossiter JP, Repke JT, Morales AJ, et al. A prospective longitudinal evaluation of pregnancy in the Marfan syndrome. Am J Obstet Gynecol 1995; 173:

1599-1606.

497. Rahman J, Rahman FZ, Rahman W, et al. Obstetric and gynecologic complications in women with Marfan syndrome. J Reprod Med 2003; 48: 723-

728.

498. Deanfield J, Thaulow E, Warnes C, et al. Task Force on the Management of Grown Up Congenital Heart Disease, European Society of Cardiology.

ESC Committee for Practice Guidelines. Management of grown up congenital heart disease. Eur Heart J 2003; 24: 1035-1084.

499. Perloff JK, Koos B. Pregnancy and congenital heart disease: the mother and the fetus. (Perloff JK, Child JS eds), Congenital Heart Disease in Adults

2nd ed. W. B. Saunders, Philadelphia 1998: 144-164.

500. Cunningham FG. Cardiovascular Disease. Williams Obstetrics22th. Cunningham. Mcgraw-Hill 2005; 1017-1041.

文献